What is the primary purpose of this 10-Q filing?

This 10-Q filing is a quarterly report filed by Abbott Laboratories (ABT) with the U.S. Securities and Exchange Commission (SEC). Its primary purpose is to provide investors and the public with an update on the company's financial performance and significant business events during the third quarter of 1998.

Where can I find the actual financial details from this filing?

The provided text is a directory listing from the SEC's EDGAR system. To access the detailed financial statements, management's discussion and analysis, and other crucial information, you would need to locate and review the full .txt or HTML version of the 10-Q filing for Abbott Laboratories dated November 11, 1998.

What key financial metrics should I look for in the full 10-Q report?

Investors should look for critical financial metrics such as total revenue, cost of goods sold, operating expenses, net income (profitability), earnings per share (EPS), cash flow from operations, and the company's balance sheet (assets, liabilities, and equity) to assess Abbott's financial health and performance during the quarter.

What are the main business segments of Abbott Laboratories around 1998?

Historically, Abbott Laboratories operated in several key segments, including pharmaceuticals, medical diagnostics, nutritional products, and possibly medical devices or hospital products. Examining the full report would reveal how each of these segments performed during the third quarter of 1998.

ABT 10-Q Quarterly Report Q3 FY1998 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' (ABT) 10-Q filing for the period ending September 29, 1998, indicates the company is navigating a period of operational and financial reporting. While the provided text is primarily the EDGAR filing system's directory listing and does not contain specific financial figures or management commentary, investors should note that this filing marks Abbott's quarterly update. The lack of detailed financial data in this excerpt means further investigation into the actual .txt or HTML filing documents is crucial for a comprehensive understanding of the company's performance, revenue, profitability, and any significant business developments during the third quarter of 1998. Investors should be aware that this filing covers a period in the late 1990s, a dynamic time for the healthcare and diagnostics industries. Key areas to scrutinize in the full report would include sales trends across Abbott's product segments (e.g., pharmaceuticals, diagnostics, nutritional products), any significant research and development expenditures, potential acquisitions or divestitures, and the company's overall financial health. Understanding these elements is vital for assessing Abbott's strategic direction and its ability to generate shareholder value in that historical context.

Key Highlights

1The filing pertains to Abbott Laboratories (ABT) for the period ending September 29, 1998, filed on November 11, 1998.
2This document is a 10-Q Quarterly Report, providing a look into the company's financial performance during the third quarter of 1998.
3The provided text is an EDGAR system directory listing, not the full financial report, necessitating a review of the actual filing documents for detailed financial information.
4Investors need to examine the full report to understand revenue, expenses, net income, and cash flow for the quarter.
5Key business segments of Abbott (pharmaceuticals, diagnostics, nutritional products, medical devices) should be analyzed for performance trends.
6The filing represents historical financial data from the late 1990s, relevant for understanding long-term company trajectory and past performance.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 1998

Summary

Key Highlights

Frequently Asked Questions